Form 4: Quest Diagnostics SVP Sells Shares

Quest Diagnostics SVP Patrick Plewman exercised stock options and sold 4,532 shares of common stock under a pre-arranged Rule 10b5-1 plan.

Summary

• Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics Inc. (DGX), engaged in a stock transaction.
• On August 19, 2025, Mr. Plewman exercised 4,532 non-qualified stock options at an exercise price of $112.17 per share.
• Concurrently, he sold 4,532 shares of common stock at a price of $183 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 sales plan.
• Following these transactions, Mr. Plewman directly owns 17,244 shares of Quest Diagnostics common stock and no derivative securities.

Sentiment

Score: 5

Explanation: The sale of shares by a Senior Vice President is generally viewed as a neutral to slightly negative signal, as it reduces insider ownership. However, the transaction was conducted under a pre-arranged Rule 10b5-1 plan, which suggests the sale was for personal financial planning rather than a reaction to new, adverse company information, thus mitigating the negative sentiment.

Positives

• The transactions were conducted under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a discretionary sale based on new, non-public information.
• The exercise price of $112.17 is significantly lower than the sale price of $183, indicating a profitable transaction for the insider.

Negatives

• An insider, a Senior Vice President, sold 4,532 shares of common stock, which can sometimes be perceived negatively by the market, even if under a 10b5-1 plan.

Future Outlook

No forward-looking statements or guidance are provided.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide information relevant to broader industry trends or competitor analysis.

Related Party Transactions

• The reported transaction involves an officer of the company exercising and selling company stock, which is a related party transaction as per SEC reporting requirements.

Stakeholder Impact

• Shareholders: The sale by a senior executive could be perceived as a slight negative, but the Rule 10b5-1 plan mitigates concerns about the executive's confidence in the company's future. The number of shares sold is relatively small compared to the total outstanding shares, so the direct market impact is likely minimal.
• Employees, Customers, Suppliers, Creditors: This specific insider transaction has no direct or material impact on these stakeholder groups.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled insider transaction (exercise of options and sale of shares) under a Rule 10b5-1 plan. While an insider sale can sometimes be a negative signal, the pre-arranged nature of the transaction suggests it is for personal financial management rather than a reflection of a change in the company's fundamental outlook. The filing does not contain new information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide a basis for a buy or sell decision.

Keywords

Quest Diagnostics, DGX, Patrick Plewman, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1, SVP, Diagnostic Services